CRDF

Cardiff OncologyA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$2.25

+155.7% vs current

Most likely

Base case

50%

Probability

Target price

$0.80

-9.1% vs current

B-

Bear case

25%

Probability

Target price

$0.35

-60.2% vs current

AI sentiment snapshot

Latest data as of 2026-07-16

AI commentary

Primary company and SEC materials are clinically constructive, especially around CRDF-004 and the FDA-aligned Phase 3 path. However, the deterministic prior remains negative, analyst revision data are unavailable, social coverage is absent, and the available peers are only loose same-sector market-cap screens rather than validated direct operating comparators. This supports cautious monitoring rather than a high-conviction bullish stance.

RankAlpha Sentiment Codex - 2026-07-16

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-07-31eventPhase 3 design and regulatory-strategy disclosureHigh impact

Cardiff said it completed an End-of-Phase 2 FDA meeting, selected 30 mg onvansertib with FOLFIRI/bevacizumab, and planned to provide additional Phase 3 details and regulatory strategy in mid-2026 [#SEC-8K-2026-05-14] ([SEC exhibit](https://www.sec.gov/Archives/edgar/data/1213037/000121303726000013/crdf-ex99_1.htm)).

2026-07-31catalystContinued CRDF-004 data digestionHigh impact

The June 2 company-published update reported 72.2% confirmed ORR for the selected 30 mg onvansertib arm versus 42.1% for standard of care, with immature median PFS. Further market digestion could support a modest rerating, but small-sample and durability uncertainty remain [#PR-EARNINGS-2026-06-02] ([company release](https://investors.cardiffoncology.com/news-releases/news-release-details/cardiff-oncology-announces-presentation-positive-results-its)).

2026-12-31catalystPhase 3 execution and financing pathHigh impact

A successful transition from the Phase 2 signal to Phase 3 initiation could materially improve valuation, but execution timing and funding remain unproven. The Q1 update reported approximately $46.1 million of cash, cash equivalents, and short-term investments and approximately $12.3 million of quarterly operating cash use, creating dilution and runway sensitivity as development advances [#SEC-8K-2026-05-14].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-16 • Updated nightlySource: Internal modelMethodology